<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6204">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03026166</url>
  </required_header>
  <id_info>
    <org_study_id>M16-300</org_study_id>
    <secondary_id>2016-003686-26</secondary_id>
    <nct_id>NCT03026166</nct_id>
  </id_info>
  <brief_title>A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer</brief_title>
  <official_title>A Phase 1/2 Study on the Safety of Rovalpituzumab Tesirine Administered in Combination With Nivolumab or Nivolumab and Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this multicenter, Phase 1/2, open-label, study is to assess the safety and
      efficacy of rovalpituzumab tesirine administered in combination with nivolumab or nivolumab
      and ipilimumab in participants with extensive-stage small cell lung cancer (SCLC).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with dose-limiting toxicities (DLT)</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>ORR is defined as the percentage of participants whose best overall response is either complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (CBR)</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>CBR is defined as the percentage of participants who, after the first dose of study drug, achieve a best response of stable disease (SD) or better for a duration of at least 4 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>DOR is defined as the time from the initial objective response to disease progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>PFS time is defined as the time from the first dose of study drug to progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS status after 6 months from the initiation of study treatment</measure>
    <time_frame>Approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>OS is defined as number of days from the date of first dose to the date of death.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Rovalpituzumab Tesirine and nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rovalpituzumab tesirine 0.3 mg/kg intravenous (various dose regimens) and nivolumab intravenous (various doses and dose regimens)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rovalpituzumab Tesirine and nivolumab plus ipilimumab 1 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rovalpituzumab tesirine 0.3 mg/kg intravenous (various dose regimens) and nivolumab intravenous (various doses and dose regimens) plus ipilimumab 1 mg/kg intravenous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rovalpituzumab Tesirine and nivolumab plus ipilimumab 3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rovalpituzumab tesirine 0.3 mg/kg intravenous (various dose regimens) and nivolumab intravenous (various doses and dose regimens) plus ipilimumab 3 mg/kg intravenous</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rovalpituzumab tesirine</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>Rovalpituzumab Tesirine and nivolumab</arm_group_label>
    <arm_group_label>Rovalpituzumab Tesirine and nivolumab plus ipilimumab 1 mg/kg</arm_group_label>
    <arm_group_label>Rovalpituzumab Tesirine and nivolumab plus ipilimumab 3 mg/kg</arm_group_label>
    <other_name>SC16LD6.5</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nivolumab</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>Rovalpituzumab Tesirine and nivolumab</arm_group_label>
    <arm_group_label>Rovalpituzumab Tesirine and nivolumab plus ipilimumab 1 mg/kg</arm_group_label>
    <arm_group_label>Rovalpituzumab Tesirine and nivolumab plus ipilimumab 3 mg/kg</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ipilimumab</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>Rovalpituzumab Tesirine and nivolumab</arm_group_label>
    <arm_group_label>Rovalpituzumab Tesirine and nivolumab plus ipilimumab 1 mg/kg</arm_group_label>
    <arm_group_label>Rovalpituzumab Tesirine and nivolumab plus ipilimumab 3 mg/kg</arm_group_label>
    <other_name>Yervoy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with histologically or cytologically confirmed extensive-stage small
             cell lung cancer (SCLC) with progressive disease after at least one platinum-based
             chemotherapeutic regimen and with evaluable or measurable disease

          -  Eastern Cooperative Oncology Group (ECOG) 0-1

          -  Adequate hematologic, hepatic, and renal function

        Exclusion Criteria:

          -  Has active, known, or suspected autoimmune disease

          -  Had prior exposure to an immuno-oncology or pyrrolobenzodiazepine (PBD)-based drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charity Scripture, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>M16-300 Study_Team</last_name>
    <email>stem-m16-300_alerts@abbvie.com</email>
  </overall_contact>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 30, 2017</lastchanged_date>
  <firstreceived_date>January 18, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nivolumab</keyword>
  <keyword>Ipilimumab</keyword>
  <keyword>Rovalpituzumab tesirine</keyword>
  <keyword>Cancer</keyword>
  <keyword>Extensive-Stage Small Cell Lung Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
